JP2019528061A5 - - Google Patents

Download PDF

Info

Publication number
JP2019528061A5
JP2019528061A5 JP2019508259A JP2019508259A JP2019528061A5 JP 2019528061 A5 JP2019528061 A5 JP 2019528061A5 JP 2019508259 A JP2019508259 A JP 2019508259A JP 2019508259 A JP2019508259 A JP 2019508259A JP 2019528061 A5 JP2019528061 A5 JP 2019528061A5
Authority
JP
Japan
Prior art keywords
cancer
seq
amino acid
acid sequence
antigen recognition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2019508259A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019528061A (ja
JP6964351B2 (ja
Filing date
Publication date
Priority claimed from DE102016115246.3A external-priority patent/DE102016115246C5/de
Application filed filed Critical
Publication of JP2019528061A publication Critical patent/JP2019528061A/ja
Publication of JP2019528061A5 publication Critical patent/JP2019528061A5/ja
Priority to JP2021128303A priority Critical patent/JP2021184729A/ja
Application granted granted Critical
Publication of JP6964351B2 publication Critical patent/JP6964351B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2019508259A 2016-08-17 2017-07-04 新規t細胞受容体およびそれを用いた免疫療法 Active JP6964351B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2021128303A JP2021184729A (ja) 2016-08-17 2021-08-04 新規t細胞受容体およびそれを用いた免疫療法

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201662376059P 2016-08-17 2016-08-17
US62/376,059 2016-08-17
DE102016115246.3 2016-08-17
DE102016115246.3A DE102016115246C5 (de) 2016-08-17 2016-08-17 Neue t-zellrezeptoren und deren verwendung in immuntherapie
US201662376632P 2016-08-18 2016-08-18
US62/376,632 2016-08-18
PCT/EP2017/066630 WO2018033291A1 (en) 2016-08-17 2017-07-04 T cell receptors and immune therapy using the same

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2021128303A Division JP2021184729A (ja) 2016-08-17 2021-08-04 新規t細胞受容体およびそれを用いた免疫療法

Publications (3)

Publication Number Publication Date
JP2019528061A JP2019528061A (ja) 2019-10-10
JP2019528061A5 true JP2019528061A5 (cg-RX-API-DMAC7.html) 2020-02-20
JP6964351B2 JP6964351B2 (ja) 2021-11-10

Family

ID=60419980

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2019508259A Active JP6964351B2 (ja) 2016-08-17 2017-07-04 新規t細胞受容体およびそれを用いた免疫療法
JP2021128303A Pending JP2021184729A (ja) 2016-08-17 2021-08-04 新規t細胞受容体およびそれを用いた免疫療法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2021128303A Pending JP2021184729A (ja) 2016-08-17 2021-08-04 新規t細胞受容体およびそれを用いた免疫療法

Country Status (18)

Country Link
US (2) US10550182B2 (cg-RX-API-DMAC7.html)
EP (1) EP3500593B1 (cg-RX-API-DMAC7.html)
JP (2) JP6964351B2 (cg-RX-API-DMAC7.html)
CN (1) CN109563149A (cg-RX-API-DMAC7.html)
AU (2) AU2017312361B2 (cg-RX-API-DMAC7.html)
BR (1) BR112019001922A2 (cg-RX-API-DMAC7.html)
CA (1) CA3031995A1 (cg-RX-API-DMAC7.html)
CR (1) CR20190095A (cg-RX-API-DMAC7.html)
DE (1) DE102016115246C5 (cg-RX-API-DMAC7.html)
DK (1) DK3500593T3 (cg-RX-API-DMAC7.html)
LT (1) LT3500593T (cg-RX-API-DMAC7.html)
MA (1) MA45976B1 (cg-RX-API-DMAC7.html)
MX (1) MX395287B (cg-RX-API-DMAC7.html)
PE (1) PE20190477A1 (cg-RX-API-DMAC7.html)
RS (1) RS62498B1 (cg-RX-API-DMAC7.html)
SG (1) SG11201900955VA (cg-RX-API-DMAC7.html)
TW (1) TWI775768B (cg-RX-API-DMAC7.html)
WO (1) WO2018033291A1 (cg-RX-API-DMAC7.html)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021173560A1 (en) 2020-02-24 2021-09-02 Immatics US, Inc. Methods for expanding t cells for the treatment of cancer and related malignancies
GB201423361D0 (en) * 2014-12-30 2015-02-11 Immatics Biotechnologies Gmbh Method for the absolute Quantification of naturally processed HLA-Restricted cancer peptides
ZA201900664B (en) * 2016-08-17 2021-09-29 Paul Ehrlich Strasse 15 Tuebingen 72076 Germany T cell receptors and immune therapy using the same
SG11201908527SA (en) * 2017-03-15 2019-10-30 Hutchinson Fred Cancer Res High affinity mage-a1-specific tcrs and uses thereof
EP3675897A1 (en) 2017-09-01 2020-07-08 Dana Farber Cancer Institute, Inc. Immunogenic peptides specific to bcma and taci antigens for treatment of cancer
MX2020004741A (es) 2017-11-06 2020-09-18 Immatics Biotechnologies Gmbh Nuevos receptores de las celulas t modificados geneticamente y terapias immunologicas que emplean los mismos.
DE102017125888A1 (de) 2017-11-06 2019-05-23 Immatics Biotechnologies Gmbh Neue konstruierte T-Zell-Rezeptoren und deren Verwendung in Immuntherapie
AU2019218093A1 (en) 2018-02-09 2020-09-10 Immatics US, Inc. Methods for manufacturing T cells
DE102018108612A1 (de) 2018-03-21 2019-09-26 Immatics US, Inc. Verfahren zur erhöhung der persistenz von adoptiv infundierten t-zellen
CN112292037B (zh) 2018-06-19 2024-03-22 帝斯曼知识产权资产管理有限公司 脂解酶变体
CN120607607A (zh) * 2019-01-22 2025-09-09 美国卫生和人力服务部 针对含有g12r突变的ras的hla第ii类限制性t细胞受体
US12448429B2 (en) 2019-03-06 2025-10-21 Dana-Farber Cancer Institute, Inc. T cell receptors specific to b-cell maturation antigen for treatment of cancer
DE102019108125B4 (de) 2019-03-28 2022-02-03 Immatics US, Inc. Cd28 t-zellkulturen, zusammensetzungen und verfahren zu deren verwendung
US20200297768A1 (en) 2019-03-19 2020-09-24 Immatics US, Inc. Cd28 t cell cultures, compositions, and methods of using thereof
PH12021552979A1 (en) 2019-05-27 2023-10-09 Immatics Us Inc Viral vectors and their use in adoptive cellular therapy
ES2991645T3 (es) 2019-06-06 2024-12-04 Immatics Biotechnologies Gmbh Clasificación con contraselección mediante péptidos de secuencia similar
US20210032370A1 (en) 2019-08-02 2021-02-04 Immatics Biotechnologies Gmbh Recruiting agent further binding an mhc molecule
DE102020106710A1 (de) 2020-03-11 2021-09-16 Immatics US, Inc. Wpre-mutantenkonstrukte, zusammensetzungen und zugehörige verfahren
DE102020111571A1 (de) 2020-03-11 2021-09-16 Immatics US, Inc. Wpre-mutantenkonstrukte, zusammensetzungen und zugehörige verfahren
US20230227526A1 (en) * 2020-06-09 2023-07-20 Board Of Regents, The University Of Texas System Engineered t cell receptors and methods of use
WO2022040631A1 (en) 2020-08-21 2022-02-24 Immatics US, Inc. Methods for isolating cd8+ selected t cells
MX2023007817A (es) 2020-12-31 2023-09-13 Immatics Us Inc Polipéptidos de cd8, composiciones y métodos de uso de estos.
DE102021100038A1 (de) 2020-12-31 2022-06-30 Immatics US, Inc. Modifizierte cd8-polypeptide, zusammensetzungen und verfahren zu deren verwendung
MX2023012899A (es) 2021-05-05 2023-11-08 Immatics Biotechnologies Gmbh Polipeptidos de union a antigeno bma031 mejorados.
JP2024534825A (ja) 2021-08-24 2024-09-26 イマティクス ユーエス,アイエヌシー. 条件付きリガンド交換により産生されたペプチドmhc複合体を使用する免疫細胞の選択
WO2023044488A1 (en) 2021-09-20 2023-03-23 Immatics US, Inc. Monocyte depletion of t cells populations for t-cell therapy
US20230192886A1 (en) 2021-11-08 2023-06-22 Immatics Biotechnologies Gmbh Adoptive cell therapy combination treatment and compositions thereof
US20230142468A1 (en) 2021-11-08 2023-05-11 Immatics US, Inc. Methods for generating cell spheroids
WO2023212691A1 (en) 2022-04-28 2023-11-02 Immatics US, Inc. DOMINANT NEGATIVE TGFβ RECEPTOR POLYPEPTIDES, CD8 POLYPEPTIDES, CELLS, COMPOSITIONS, AND METHODS OF USING THEREOF
JP2025515603A (ja) 2022-04-28 2025-05-20 イマティクス ユーエス,アイエヌシー. Il-12ポリペプチド、il-15ポリペプチド、il-18ポリペプチド、cd8ポリペプチド、それらの組成物、およびそれらの使用方法
EP4514829A1 (en) 2022-04-28 2025-03-05 Immatics US, Inc. Membrane-bound il-15, cd8 polypeptides, cells, compositions, and methods of using thereof
US20230355678A1 (en) 2022-05-05 2023-11-09 Immatics US, Inc. Methods for improving t cell efficacy
CN117946247B (zh) * 2023-02-23 2024-08-09 暨南大学 一种识别mage-a3抗原短肽的t细胞受体及其应用
WO2025096649A1 (en) 2023-11-01 2025-05-08 Immatics US, Inc. Membrane-bound il-15, cd8 polypeptides, cells, compositions, and methods of using thereof

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992003918A1 (en) 1990-08-29 1992-03-19 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5714352A (en) 1996-03-20 1998-02-03 Xenotech Incorporated Directed switch-mediated DNA recombination
WO2001058479A1 (en) 2000-02-08 2001-08-16 The Penn State Research Foundation Immunotherapy using interleukin 13 receptor subunit alpha 2
US7820401B2 (en) * 2004-08-23 2010-10-26 Albert Einstein College Of Medicine Of Yeshiva University Collagen VI and cancer
EP1762575A1 (en) * 2005-09-12 2007-03-14 Ganymed Pharmaceuticals AG Identification of tumor-associated antigens for diagnosis and therapy
US8105831B2 (en) * 2007-03-09 2012-01-31 University Of Washington Parvoviral production of HLA homozygous cells
GB0911566D0 (en) 2009-07-03 2009-08-12 Immunocore Ltd T cell receptors
US9228007B1 (en) * 2010-03-11 2016-01-05 The Regents Of The University Of California Recombinant human progenitor cells, engineered human thymocytes, and engineered human T cells
GB201004551D0 (en) * 2010-03-19 2010-05-05 Immatics Biotechnologies Gmbh NOvel immunotherapy against several tumors including gastrointestinal and gastric cancer
ES2973064T3 (es) * 2013-07-15 2024-06-18 Us Health Receptores de células T frente al virus del papiloma humano 16 E6
AU2015289644A1 (en) * 2014-07-15 2017-02-02 Juno Therapeutics, Inc. Engineered cells for adoptive cell therapy
EP3753948A1 (en) * 2014-11-05 2020-12-23 Genentech, Inc. Methods of producing two chain proteins in bacteria

Similar Documents

Publication Publication Date Title
JP2019528061A5 (cg-RX-API-DMAC7.html)
JP2019088286A5 (cg-RX-API-DMAC7.html)
JP2022058932A5 (cg-RX-API-DMAC7.html)
JP2017186337A5 (cg-RX-API-DMAC7.html)
JP2019511222A5 (cg-RX-API-DMAC7.html)
JP2019536430A5 (cg-RX-API-DMAC7.html)
JP2023139070A5 (cg-RX-API-DMAC7.html)
JP2020500523A5 (cg-RX-API-DMAC7.html)
JP2009505676A5 (cg-RX-API-DMAC7.html)
JP2020511152A5 (cg-RX-API-DMAC7.html)
JP2010531140A5 (cg-RX-API-DMAC7.html)
JP2016505513A5 (cg-RX-API-DMAC7.html)
JP2020512019A5 (cg-RX-API-DMAC7.html)
JP2012529281A5 (cg-RX-API-DMAC7.html)
JP2020510653A5 (ja) Ceaを標的にする多重特異性結合タンパク質
JP2016521692A5 (cg-RX-API-DMAC7.html)
JP2011518886A5 (cg-RX-API-DMAC7.html)
JPWO2020237227A5 (cg-RX-API-DMAC7.html)
JP2020522474A5 (cg-RX-API-DMAC7.html)
JP2011157397A5 (cg-RX-API-DMAC7.html)
JP2010110329A5 (cg-RX-API-DMAC7.html)
JP2012525149A5 (cg-RX-API-DMAC7.html)
CN102317318A (zh) 抗cd160单克隆抗体及其用途
RU2013104830A (ru) Лечение рака при помощи направленных на мишень антител in vivo
CN113710688A (zh) 用于治疗血液癌症和实体瘤癌症的嵌合抗原受体修饰的t细胞(car-t)